| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | ACEH |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human ACE2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与ACE2抗体相关的研究文献摘要概览：
---
1. **文献名称**: *A humanized monoclonal antibody blocking SARS-CoV-2 infection*
**作者**: Yuan M et al.
**摘要**: 该研究报道了一种人源化单克隆抗体(H11-D4)，通过靶向ACE2受体结合域(RBD)，有效阻断SARS-CoV-2刺突蛋白与ACE2的结合，在体外和动物模型中展示出中和病毒感染的潜力，为COVID-19治疗提供候选抗体。
---
2. **文献名称**: *Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2*
**作者**: Yan R et al.
**摘要**: 通过冷冻电镜解析ACE2与SARS-CoV-2刺突蛋白复合物的结构，揭示了ACE2受体结合界面的关键位点，为设计靶向ACE2的中和抗体或抑制剂提供了结构生物学基础，助力抗病毒药物开发。
---
3. **文献名称**: *Cross-reactive antibodies after SARS-CoV-2 infection and vaccination*
**作者**: Shrock E et al.
**摘要**: 研究分析了COVID-19康复者及疫苗接种者的抗体库，发现部分抗体能交叉结合ACE2的不同表位，可能对其他冠状病毒(如SARS-CoV-1)具有中和活性，提示ACE2靶向抗体的广谱治疗潜力。
---
**备注**：上述文献均发表于2020-2021年，集中于ACE2抗体在抗病毒(尤其是SARS-CoV-2)领域的机制与应用。如需具体期刊或补充文献，可进一步提供研究方向(如非病毒疾病中的ACE2抗体研究)。
ACE2 (angiotensin-converting enzyme 2) is a membrane-bound enzyme primarily expressed in the lungs, heart, kidneys, and intestines. It plays a critical role in the renin-angiotensin system (RAS) by counterbalancing ACE activity, converting angiotensin II into angiotensin-(1-7) to regulate blood pressure and cardiovascular function. Notably, ACE2 serves as the functional receptor for SARS-CoV and SARS-CoV-2. enabling viral entry into host cells via spike protein interaction.
ACE2-targeting antibodies have gained prominence in biomedical research, particularly in COVID-19 therapeutics. Neutralizing antibodies against ACE2 can block viral attachment, potentially inhibiting infection. Additionally, ACE2 antibodies are used as research tools to study tissue distribution, enzymatic activity, and RAS-related pathologies like hypertension and diabetes. Some therapeutic strategies explore soluble ACE2 decoys or antibody-mediated ACE2 modulation to mitigate viral entry or organ damage.
However, ACE2 antibodies present dual implications. While inhibiting ACE2 may reduce viral infectivity, excessive blockade could disrupt its physiological protective roles in reducing inflammation, fibrosis, and oxidative stress. Current research focuses on developing antibodies that specifically neutralize viral binding without compromising ACE2's enzymatic functions. These antibodies also hold diagnostic value for quantifying ACE2 expression in diseases or evaluating COVID-19 susceptibility. Ongoing studies aim to optimize their therapeutic window for both antiviral and cardiometabolic applications.
×
